Olivia T Van Gerwen1, Ashutosh Tamhane1, Andrew O Westfall1, Michael J Mugavero1, Heidi M Crane2, Richard D Moore3, Maile Karris4, Katerina Christopoulos5, Julia C Dombrowski2, Kenneth H Mayer6, Jeanne Marrazzo1, Jodie Dionne-Odom1. 1. From the Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL. 2. Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA. 3. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD. 4. Department of Medicine, Division of Infectious Diseases, University of California at San Diego, San Diego. 5. Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA. 6. Fenway Health and Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Data on testing rates and prevalence of and factors associated with genital and extragenital chlamydia and gonorrhea among transgender women with HIV in the United States are limited. METHODS: This retrospective cohort analysis included transgender women living with HIV enrolled in the US Centers for AIDS Research Network of Integrated Clinical Systems cohort between January 2005 and December 2016 with chlamydia or gonorrhea testing performed in HIV clinic. The primary outcome was a positive test result for chlamydia or gonorrhea at urogenital or extragenital (rectal/pharyngeal) sites. Factors associated with infection were examined using logistic regression and generalized estimating equations to account for multiple tests per woman. RESULTS: Among 312 transgender women in HIV care, 252 (81%) were tested for chlamydia or gonorrhea at least once. Annual testing rates were low: 23% to 53% at genital sites and 24% to 47% at extragenital sites. A total of 88 infections were detected, and 22% of women (55/252) had at least one positive test result. Most infections occurred at extragenital sites (80% of chlamydia and 82% of gonorrhea positive test results). Factors associated with infection in an adjusted model were as follows: age 18 to 29 years compared with ≥50 years (adjusted odds ratio [aOR], 7.6; 95% confidence interval [CI], 1.8-31.2), CD4 count >350 compared with CD4 <200 (aOR, 5.5; 95% CI, 1.2-25.1), and higher engagement in HIV care (aOR, 2.2; 95% CI, 1.0-4.5). CONCLUSIONS: Among transgender women living with HIV, testing rates for chlamydia and gonorrhea are inadequate, particularly at extragenital sites where most infections occur.
BACKGROUND: Data on testing rates and prevalence of and factors associated with genital and extragenital chlamydia and gonorrhea among transgender women with HIV in the United States are limited. METHODS: This retrospective cohort analysis included transgender women living with HIV enrolled in the US Centers for AIDS Research Network of Integrated Clinical Systems cohort between January 2005 and December 2016 with chlamydia or gonorrhea testing performed in HIV clinic. The primary outcome was a positive test result for chlamydia or gonorrhea at urogenital or extragenital (rectal/pharyngeal) sites. Factors associated with infection were examined using logistic regression and generalized estimating equations to account for multiple tests per woman. RESULTS: Among 312 transgender women in HIV care, 252 (81%) were tested for chlamydia or gonorrhea at least once. Annual testing rates were low: 23% to 53% at genital sites and 24% to 47% at extragenital sites. A total of 88 infections were detected, and 22% of women (55/252) had at least one positive test result. Most infections occurred at extragenital sites (80% of chlamydia and 82% of gonorrhea positive test results). Factors associated with infection in an adjusted model were as follows: age 18 to 29 years compared with ≥50 years (adjusted odds ratio [aOR], 7.6; 95% confidence interval [CI], 1.8-31.2), CD4 count >350 compared with CD4 <200 (aOR, 5.5; 95% CI, 1.2-25.1), and higher engagement in HIV care (aOR, 2.2; 95% CI, 1.0-4.5). CONCLUSIONS: Among transgender women living with HIV, testing rates for chlamydia and gonorrhea are inadequate, particularly at extragenital sites where most infections occur.
Authors: Jeffrey S Becasen; Christa L Denard; Mary M Mullins; Darrel H Higa; Theresa Ann Sipe Journal: Am J Public Health Date: 2018-11-29 Impact factor: 9.308
Authors: Matthew J Mimiaga; Sari L Reisner; Chris Grasso; Heidi M Crane; Steven A Safren; Mari M Kitahata; Joseph E Schumacher; W Christopher Mathews; Kenneth H Mayer Journal: Am J Public Health Date: 2013-06-13 Impact factor: 9.308
Authors: Jeffrey H Herbst; Elizabeth D Jacobs; Teresa J Finlayson; Vel S McKleroy; Mary Spink Neumann; Nicole Crepaz Journal: AIDS Behav Date: 2007-08-13
Authors: Alessandra Anna Secco; Hana Akselrod; Jonathan Czeresnia; Matthew Levy; Morgan Byrne; Anne Monroe; Jose Lucar; Michael Horberg; Amanda Derryck Castel; Rupali Doshi; Heather Rivasplata; Leah Squires; David Parenti; Debra Benator Journal: Sex Transm Infect Date: 2020-01-06 Impact factor: 3.519
Authors: Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag Journal: Int J Epidemiol Date: 2008-02-08 Impact factor: 7.196
Authors: Chelsea L Shannon; Erin M Keizur; Anne Fehrenbacher; Drew Wood-Palmer; Wilson Ramos; Maryann Koussa; Jasmine Fournier; Sung-Jae Lee; Dhara Patel; Whitney N Akabike; Sue Ellen Abdalian; Mary Jane Rotheram-Borus; Jeffrey D Klausner Journal: Sex Transm Dis Date: 2019-11 Impact factor: 3.868
Authors: Maria C Geba; Samuel Powers; Brooke Williams; Kathryn R Dort; Elizabeth T Rogawski McQuade; Kathleen A McManus Journal: Open Forum Infect Dis Date: 2022-07-01 Impact factor: 4.423